A new player is taking the field in a push for a hemophilia A gene therapy, and it’s a big one
BioMarin, the execs at Spark (and buyer-to-be Roche) as well as the Sangamo/Pfizer team have a new rival striding onto the hemophilia block. And it’s a big one.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 63,000+ biopharma pros reading Endpoints daily — and it's free.